🔗 Share this article

While the US undertakes historic revisions to its vaccination guidelines, one figure appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by casting doubt on COVID-19 shots during the pandemic and has focused upon possible fatalities following COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Program

Health officials were set to reveal sweeping changes to the childhood vaccination calendar in December, bringing the US with Denmark’s vaccine program, it is understood – a major change that would put the US out of step with much of the international standard with insufficient data for benefit. The planned update has been delayed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to address the audience at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this year.

A Shift at the FDA

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics branches as Høeg and Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon dismantling previously authorized vaccines at the FDA.

The new acting director has often pushed for ending specific pediatric vaccine recommendations in the US to become more in line with Denmark's approach, a country with comprehensive healthcare and a population approximately the size of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on immunizations – typically the responsibility of Dr. Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Background

The appointee has no obvious track record in drug development, oversight or administrative roles, which has been typical for former directors of the biologics center. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, said Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a major agency. She lacks background in drug approvals.”

Previous commissioners of CBER would “be deeply familiar with legal statutes and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Frankly, she lacks the type of experience that prior appointees who headed CBER have had.”

CDER has an vast portfolio at the FDA, she emphasized.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office clears numerous generic drugs. There is also a biosimilars program, over-the-counter program and so forth, and every single one have to be supervised,” she noted. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

Furthermore, a major administrative element to the position, which oversees over 5,000 staff members. “It is a enormous leadership role, if you execute it properly,” she concluded.

Official Statement and Controversial Policies

When asked about inquiries about Dr. Høeg's credentials and whether this assignment indicates greater collaboration among regulatory chiefs on immunizations, a press secretary stated that the “inquiries are based on flawed premises”.

“This background aligns with the responsibilities of her position,” the representative stated, pointing to the period Dr. Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a controversial expedited medication authorization process that apparently worried her preceding directors. “How are these drugs being picked for this voucher program? Who makes the choices?” Howard questioned. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards laxer regulations of pharmaceuticals, except for vaccines.”

Established Track Record on Vaccines

With vaccines, Høeg has a more established, if troubling, past, some experts observe. She authored a analysis using unconfirmed public submissions to assess the rate of heart inflammation after Covid immunization. She consulted for the state of Florida top health official Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are riskier than they are.

Included in her “desired changes” for the incoming federal leadership included changing regulations for new vaccines and halting “optional” immunizations, she remarked after the election on a audio program. At the FDA, Høeg has reportedly floated the idea of barring teenage boys from receiving COVID-19 vaccinations.

“She is an thorough ideologue who begins with her conclusions and tailors the evidence to fit the evidence in a very misleading, fraudulent manner,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|